Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Neuphoria Therapeutics (BNOXN) Stock Price & Analysis

BNOXN Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
MXN 310.15M
Enterprise Value
N/A
Total Cash (Recent Filing)
MXN 19.87M
Total Debt (Recent Filing)
MXN 34.34K
Price to Earnings (P/E)
―
Beta
0.13
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Equity Base

A low-debt balance sheet provides financial flexibility while the sizable equity base offers capacity to support development and strategic investment. Although returns remain weak, limited leverage reduces immediate balance-sheet pressure and may help the company pursue its biotech plans without excessive interest obligations.

Merger And Financing Runway

The proposed combination with Scancell and associated financing could materially strengthen funding durability by supporting a registrational Phase 3 trial and extending runway into 2029. A longer financing horizon may reduce near-term capital pressure and enable sustained investment in the combined immunotherapy pipeline.

Revenue Step-Up

The sharp increase in reported revenue indicates that the company has begun moving beyond the minimal revenue base seen in earlier periods. While the trend is not yet stable or profitable, continued commercialization or collaboration-related revenue growth could improve operating leverage and broaden future funding options.

Bears Say

Persistent Unprofitability

Persistent losses and an extremely negative net margin show that current business activity is not translating into sustainable earnings. This weak profitability can continue consuming capital, limit internally funded growth, and make the company more dependent on successful development outcomes or additional external financing.

Renewed Heavy Cash Burn

The sharp return to negative operating and free cash flow indicates that cash generation remains inconsistent and sensitive to the biotech development cycle. Continued outflows could erode the company’s financial cushion and increase reliance on financing, especially if operating improvements or milestone receipts are delayed.

Merger Execution Risk

The proposed transaction and financing package are not yet fully secured because completion depends on approvals, cash requirements, and financing conditions. Delays or failure to close could weaken the intended runway extension, disrupt strategic integration, and leave the company exposed to continued funding pressure.

Neuphoria Therapeutics News

BNOXN FAQ

What is Neuphoria Therapeutics’s market cap?
Neuphoria Therapeutics’s market cap is Mex$310.15M.
When is Neuphoria Therapeutics’s upcoming earnings report date?
Neuphoria Therapeutics’s next earnings report is estimated for Aug 23, 2023 (not yet confirmed), which is 1167 days ago.
How were Neuphoria Therapeutics’s earnings last quarter?
Neuphoria Therapeutics released its earnings results on Sep 29, 2025. The company reported -Mex$45.919 earnings per share for the quarter, missing the consensus estimate of -Mex$36.264 by -Mex$9.655.
Is Neuphoria Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Neuphoria Therapeutics pay dividends?
Neuphoria Therapeutics does not currently pay dividends.
What is Neuphoria Therapeutics’s EPS estimate?
Neuphoria Therapeutics’s EPS estimate is -19.55.
How many shares outstanding does Neuphoria Therapeutics have?
Neuphoria Therapeutics has 5,411,334 shares outstanding.
What happened to Neuphoria Therapeutics’s price movement after its last earnings report?
Neuphoria Therapeutics reported an EPS of -Mex$45.919 in its last earnings report, missing expectations of -Mex$36.264. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Neuphoria Therapeutics?
Currently, no hedge funds are holding shares in MX:BNOXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology